Seminars in Oncology
Volume 35, Issue 5 , Pages 522-529, October 2008

The Half Century of Clinical Trials of the National Surgical Adjuvant Breast and Bowel Project

  • D. Lawrence Wickerham

      Affiliations

    • National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations Office, Pittsburgh, PA
    • Corresponding Author InformationAddress correspondence to D. Lawerence Wickerham, MD, NSABP, Four Allegheny Center, Pittsburgh, PA 15212
    • ,
  • Michael J. O'Connell

      Affiliations

    • National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations Office, Pittsburgh, PA
    • ,
  • Joseph P. Costantino

      Affiliations

    • NSABP Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Walter M. Cronin

      Affiliations

    • NSABP Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
    • ,
  • Soonmyung Paik

      Affiliations

    • Division of Pathology, NSABP, Pittsburgh, PA
    • ,
  • Charles E. Geyer Jr

      Affiliations

    • National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations Office, Pittsburgh, PA
    • ,
  • Patricia A. Ganz

      Affiliations

    • UCLA School of Medicine and Public Health, Jonsson Comprehensive Cancer Center, Los Angeles, CA
    • ,
  • Nicholas Petrelli

      Affiliations

    • Helen F. Graham Cancer Center, Newark, DE
    • ,
  • Eleftherios P. Mamounas

      Affiliations

    • Aultman Hospital Cancer Center, Canton, OH
    • ,
  • Thomas B. Julian

      Affiliations

    • National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations Office, Pittsburgh, PA
    • Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA
    • ,
  • Norman Wolmark

      Affiliations

    • Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported in part by National Cancer Institute Grants No. U10-CA37377, U10-CA69974, U10-CA69651, U10-CA12027, and U24-CA114732.

 Financial disclosure: D. Lawrence Wickerham, MD, Eli Lilly and Company (consulting) and AstraZeneca Pharmaceuticals (honorarium); Walter M. Cronin, MPH, AstraZeneca Pharmaceuticals (compliance advisory board); Soonmyung Paik, MD, Glaxo Smith Kline and Genentech (honorarium); Eleftherios P. Mamounas, MD, MPH, Aventis (consulting, honorarium), Genentech (consulting, honorarium), Genomic Health (honorarium), Roche (consulting), Glaxo Smith Kline (consulting), Eli Lilly (consulting).

PII: S0093-7754(08)00168-1

doi:10.1053/j.seminoncol.2008.07.005

Seminars in Oncology
Volume 35, Issue 5 , Pages 522-529, October 2008

Article Tools

* Image Usage & Resolution